Exact Sciences Corporation (EXAS)
$64.72
Rating:
Recommendation:
Buy
| Symbol | EXAS |
|---|---|
| Price | $64.72 |
| Beta | 1.418 |
| Volume Avg. | 1.44M |
| Market Cap | 11.705B |
| Shares () | - |
| 52 Week Range | 43.9-100.77 |
| 1y Target Est | - |
| DCF Unlevered | EXAS DCF -> | |
|---|---|---|
| DCF Levered | EXAS LDCF -> | |
| ROE | -9.19% | Neutral |
| ROA | -4.39% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 153.60% | Buy |
| P/E | -40.96 | Strong Sell |
| P/B | 3.75 | Strong Buy |
Latest EXAS news
About
Download (Excel)Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.